FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Purpose We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) following first-line combination-immune checkpoint inhibitor (combination-ICI) therapy for advanced melanoma. Methods We retrospectively reviewed outcomes in patients who had (1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2020-11, Vol.47 (12), p.2776-2786
Hauptverfasser:	Iravani, Amir, Osman, Medhat M., Weppler, Alison M., Wallace, Roslyn, Galligan, Anna, Lasocki, Arian, Hunter, Morgan O., Akhurst, Tim, Hofman, Michael S., Lau, Peter K. H., Kee, Damien, Au-Yeung, George, Sandhu, Shahneen, Hicks, Rodney J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Cardiology Computed tomography Endocrine disorders Enterocolitis Fluorodeoxyglucose F18 Health services Humans Imaging Immune checkpoint inhibitors Immune response Immune system Immunity Immunotherapy Ipilimumab - adverse effects Life Sciences & Biomedicine Medicine Medicine & Public Health Melanoma Melanoma - diagnostic imaging Melanoma - drug therapy Metabolic disorders Metabolic response Metabolism Middle Aged Monitoring Monoclonal antibodies Nivolumab - therapeutic use Nuclear Medicine Oncology Oncology – General Original Article Orthopedics Patients Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Radiology Radiology, Nuclear Medicine & Medical Imaging Retrospective Studies Science & Technology Solid tumors Targeted cancer therapy Telemedicine Tomography Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!